Please ensure Javascript is enabled for purposes of website accessibility

Why Orchard Therapeutics Stock Is Soaring Today

By Prosper Junior Bakiny - Aug 25, 2020 at 12:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No news is good news for this biotech company.

What happened?

Shares of Orchard Therapeutics (ORTX 8.46%) are up by 16.9% as of 12:27 p.m. EDT on Tuesday after rising by as much as 32.9% earlier today. The biotech company did not report any news that served as a catalyst for these massive gains, though, so what gives?

Here is a possible explanation. Orchard Therapeutics' stock was down by more than 60% year to date before today, and perhaps investors who finally felt as though the price was right bid up the company's shares.

Hand drawing an upward-bound graph on a chalkboard.

Image source: Getty Images.

So what

Stock prices fluctuate, sometimes by massive amounts, from one day to the next. These moves don't always make sense, and for investors focused on the long term, they rarely matter. Focusing on the fundamentals of a company rather than the day-to-day changes of its stock price is a much more fruitful endeavor. With that in mind, here is a short overview of Orchard Therapeutics. The company focuses on developing gene therapies for rare diseases.

The biotech's sole product on the market is called Strimvelis, which the European Medicines Agency approved back in 2016; the medicine isn't approved in the U.S. at this time. Strimvelis is used to treat severe combined immunodeficiency due to adenosine deaminase deficiency, a rare genetic disorder. This product does not generate much by way of revenue, however. During the first quarter, Orchard Therapeutics' net sales came in at $597,000, and the company reported a net loss of $47.5 million.

Now what

While Orchard Therapeutics does have several other candidates in its pipeline, the company remains a risky bet. There are far more attractive biotech stocks to consider buying out there, and it'd be wise to steer clear of Orchard Therapeutics for now.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Orchard Therapeutics plc Stock Quote
Orchard Therapeutics plc
ORTX
$0.64 (8.46%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.